References
- Eapen M, Giralt SA, Horowitz MM, . Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004;34:721–727.
- Thakar MS, Forman SJ.ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse?Hematology 2009;14:414–418.
- Chiang KY, Weisdorf DJ, Davies SM, . Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996;17: 39–42.
- Kedmi M, Resnick IB, Dray L, . A retrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant 2009;15:483–489.
- Blau IW, Basara N, Bischoff M, . Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Bone Marrow Transplant 2000;25:41–45.
- Bosi A, Laszlo D, Labopin M, . Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001;19:3675–3684.
- Keil F, Prinz E, Kalhs P, . Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants. Leukemia 2001;15: 355–361.
- Shaw BE, Mufti GJ, Mackinnon S, . Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 2008;42:783–789.
- Baron F, Storb R, Storer BE, . Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006;24:4150–4157.
- Radich JP, Sanders JE, Buckner CD, . Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimen. J Clin Oncol 1993:11:304–313.
- Bacigalupo A, Ballen K, Rizzo D, . Defining the intensity of conditioning regimens: working definition. Biol Blood Marrow Transplant 2009;15:1628–1633.
- Glucksberg H, Storb R, Pefer A, . Clinical manifestation of graft-versus-host-disease in human recipients of marrow from HL- A-matched sibling donors. Transplantation 1974;18:295–304.
- Filipovich AH, Weisdorf D, Pavletic S, . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: 1. diagnosis and staging working group report. Biology Blood Marrow Transplant 2005;11:945–955.
- Michallet M, Tanguy ML, Socie G, . Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 2000;108:400–407.
- Meshinchi S, Leisenring WM, Carpenter PA, . Survival after second hematopoietic stem-cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2003;9: 706–713.
- Oda M, Isoyama K, Ito E, . Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Int J Hematol 2009;89:374–382.
- Duus JE, Stiff PJ, Choi J, . Second allografts for relapsed hematologic malignancies: feasibility of using a different donor. Bone Marrow Transplant 2005;35:261–264.
- Blazar BR, Krieg AM, Taylor PA.Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood 2001;98:1217–1225.